AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
DarioHealth Corp.
Video analysis: DRIO
All videosNo video analysis for this stock yet. Request one from our team.
News: DRIO
DarioHealth (NASDAQ:DRIO) Share Price Passes Below Two Hundred Day Moving Average – Here’s What Happened
DarioHealth Corp. (NASDAQ: DRIO - Get Free Report)'s share price crossed below its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $7.74 and traded as low as $6.80. DarioHealth shares last traded at $6.82, with a volume of 6,322 shares changing hands. Wall Street
Pro Medicus (OTCMKTS:PMCUF) versus DarioHealth (NASDAQ:DRIO) Head to Head Survey
Pro Medicus (OTCMKTS:PMCUF - Get Free Report) and DarioHealth (NASDAQ: DRIO - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, earnings, valuation and dividends. Analyst Ratings This is a summary of recent ratings
Contrasting DarioHealth (NASDAQ:DRIO) and Phreesia (NYSE:PHR)
Phreesia (NYSE: PHR - Get Free Report) and DarioHealth (NASDAQ: DRIO - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability and analyst recommendations. Institutional and Insider Ownership 92.1% of Phreesia shares are
DarioHealth Corp. (DRIO) Q2 2026 Earnings Call Transcript
DarioHealth Corp. (DRIO) Q2 2026 Earnings Call Transcript
DarioHealth Q2 Earnings Call Highlights
DarioHealth NASDAQ: DRIO reported second-quarter 2026 revenue of $5.2 million, down from $5.6 million in the first quarter and $5.4 million a year earlier, as the company continued to shift away from pharmaceutical services revenue toward recurring B2B2C business.
DarioHealth Corp. (DRIO) Reports Q2 Loss, Lags Revenue Estimates
DarioHealth Corp. (DRIO) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to a loss of $2.4 per share a year ago.
DarioHealth Reports Second Quarter 2026 Financial Results
Second quarter 2026 revenue was $5.2 million, reflecting the Company's strategic decision to discontinue certain pharmaceutical-related business Gross margin increased to 62%, compared to 57% in the first quarter of 2026 and 55% in the second quarter of 2025; non-GAAP B2B2C gross margin was approximately 80% for the 10th consecutive quarter Operating loss decreased by 30% year-over-year and 11% quarter-over-quarter Operating expenses declined by 21% year-over-year and 8% quarter-over-quarter Multi-condition strategy compounding: more than 80% of the $13.1 million in contracted and late-stage annual recurring revenue ("ARR") is multi-condition Commercial momentum with three significant wins in recent weeks, led by a top-5 national health plan expansion with the potential to approximately triple Dario's potential revenue opportunity — its third such expansion — plus a 5th Fortune 50 client and a new health insurer via the Amwell channel Expanded into provider-backed clinical care delivery, accessing a larger portion of the healthcare value chain and increasing the potential revenue opportunity per client Pro forma cash of $36.8 million following $22.8 million net proceeds from at-the-market registered direct financing with participation from existing long-term shareholders and new fundamental institutional investors completed in July 2026 Conference call today, August 11, 2026 at 8:30 am ET NEW YORK, Aug. 11, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced financial results for the second quarter ended June 30, 2026. "We believe that Dario has reached an important stage where the investments made in our technology, product, and distribution infrastructure are compounding positive momentum," said Erez Raphael, Chief Executive Officer of Dario.
Dario Expands Provider-Backed Cardiometabolic Platform with New Women's Health and Sleep Solutions Aligning with Client Demand
New programs, expected to begin revenue contribution Q4 2026, extend Dario's integrated healthcare platform into two high-impact clinical categories while advancing execution of the Company's provider-backed care strategy AI-enabled programs combine digital engagement, human behavioral coaching and clinical care to improve outcomes while expanding Dario's participation in reimbursement-driven healthcare services NEW YORK, Aug. 4, 2026 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leading AI-powered healthcare technology company transforming the management of chronic conditions, today announced it has further expanded its provider-backed cardiometabolic platform with the launch of Dario Women™ and Dario Sleep™. The two new programs address important drivers of cardiometabolic health through an integrated care experience combining AI-powered engagement, behavioral support and access to licensed healthcare providers.
